Indication
Low Heart Rate
1 clinical trial
2 products
Clinical trial
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-20
Product
ChemotherapyProduct
Endocrine therapy